Complement Inhibitor Therapy for Myasthenia Gravis [PDF]
Frontiers in Immunology, 2020 Complement activation as a driver of pathology in myasthenia gravis (MG) has been appreciated for decades. The terminal complement component [membrane attack complex (MAC)] is found at the neuromuscular junctions of patients with MG.
Khaled Albazli +2 more
doaj +5 more sources
Complement inhibitor for therapy of CHAPLE. [PDF]
Nat Immunol, 2021 A new study shows successful immunotherapy of a detrimental gastrointestinal disease using the complement inhibitor eculizumab.
Yu CY, Ardoin SP.
europepmc +4 more sources
A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation [PDF]
Frontiers in Immunology, 2022 Antibody-induced complement activation may cause injury of the neuromuscular junction (NMJ) and is thus considered as a primary pathogenic factor in human myasthenia gravis (MG) and animal models of experimental autoimmune myasthenia gravis (EAMG).
Jie Song +15 more
doaj +2 more sources
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis [PDF]
Neurology and Therapy, 2023 This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu +9 more
doaj +2 more sources
The Production of Complement Inhibitor Proteins in Mammalian Cell Lines—Light at the End of the Tunnel? [PDF]
BiomedicinesTherapeutic recombinant proteins are powerful tools used for the treatment of many detrimental diseases such as diabetes, cancer, multiple sclerosis, rheumatoid arthritis, hepatitis, and many more.
Attila Szvetnik, Vilmos Tubak
doaj +2 more sources
The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report [PDF]
Frontiers in MedicineAutoimmune hemolytic anemia (AIHA) is a type of hemolytic anemia. In this condition, the body produces anti-red blood cell autoantibodies due to immune dysfunction. This results in accelerated destruction of red blood cells.
Xiaoqing Li +5 more
doaj +2 more sources
Comparative Efficacy of Complement Inhibitors in Complement Inhibitor–Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta‐Analysis of Randomized Trials [PDF]
eJHaemIntroduction Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, life‐threatening disease, caused by intravascular haemolysis by the complement system.
Rehan Ishaque +7 more
doaj +2 more sources
Implications of Complement Imbalance in COVID-19: A Molecular Mechanistic Discussion on the Importance of Complement Balance [PDF]
Iranian Journal of Immunology, 2023 Two central questions in COVID-19 treatment which should be considered are: “How does the imbalance of the complement system affect the therapeutic approaches?” and “Do we consider complement inhibitors in therapeutic protocols?”.
Mehdi Torabizadeh +5 more
doaj +1 more source
Frontiers in Immunology, 2021 Dysregulation of complement activation causes a number of diseases, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Emma Ispasanie +10 more
doaj +1 more source
Annals of Medicine, 2023 Objective Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disease characterized by chronic complement-mediated hemolysis. The concentrated outbreak of coronavirus disease 2019 (COVID-19) in China after 6 December 2022, provided an ...
Leyu Wang +5 more
doaj +1 more source